Protagonist Therapeutics Inc. leverages a proprietary technology platform to discover and develop novel peptide-based therapeutics. Headquartered in Newark, California, the company focuses on creating oral and injectable peptide drugs that offer improved safety and efficacy profiles compared to traditional small molecules and biologics. Its portfolio includes rusfertide, an injectable hepcidin mimetic in late-stage development for the rare blood disorder polycythemia vera, and icotrokinra (ICOTYDE), an oral IL-23 receptor antagonist approved for moderate-to-severe plaque psoriasis. The company also advances preclinical and early-stage programs targeting immune-mediated skin diseases, asthma, and obesity. Protagonist frequently collaborates with major pharmaceutical partners, such as Johnson & Johnson and Takeda, to accelerate the clinical development and commercialization of its drug candidates.
